Navigation Links
New technology enables faster, more efficient cell harvest: Cell therapy meeting study

A new, transformative filtration-based technology for the isolation and enrichment of cells, a critical first step in the development of therapies to repair or replace diseased or damaged tissues and organs, was found to be more efficient and faster than traditional technology used for cell separation.

These findings were presented today at the International Society for Cellular Therapy (ISCT) annual meeting in Berlin, Germany. The Pall Corporation (NYSE: PLL) Filter Harvest System was found to have the potential to become a valuable tool to help realize the promise of regenerative medicine, a field that scientists believe could produce significant breakthroughs in the treatment of heart disease, cancer, diabetes, bone injury and many other acute and chronic conditions.

Lisa Bradbury, Ph.D., Director, R&D Cell Therapy, Pall Life Sciences, presented data comparing the Pall Filter Harvest System to a traditional open-system, density gradient, centrifuge-based method for isolation of mononuclear cells (MNC) from whole blood. The Pall Filter Harvest System was found to significantly reduce processing time; it can be performed in less than 15 minutes compared to an average processing time of about 2.5 to 4 hours with the Ficoll gradient technique. The Filter Harvest System also exhibited higher yield of MNCs for significantly better recovery (60 to 95 percent) than the Ficoll method.

The Pall Filter Harvest system can be used as a closed system that adheres to Good Manufacturing Practice (cGMP), furthering the ability to comply with increasingly stringent regulations for safe, reproducible and efficacious cell products. In addition to rapid processing, the Pall system can be performed at point of use (operating room). It does not require the addition of laboratory equipment or trained technicians, as the method is easy to learn and use.

"Researchers and companies working in cell therapy expressed the need to find better and easi
'"/>

Source:Pall Corporation


Page: 1 2

Related biology news :

1. Novel technology detects human DNA mutations
2. Novel antiviral technology inhibits RSV infection in mice
3. The BIOS Initiative - open source biotechnology is born
4. Revolutionary nanotechnology illuminates brain cells at work
5. Study: homemade gene expression technology unreliable
6. First technology to remove prions that cause vCJD from blood launched
7. Integration of Agilents MS technology, Proteome Systems software to help scientists in proteomics research
8. Agilent Technologies new genome analysis technology set to accelerate Australia fight against mesothelioma
9. Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
10. First production of human monoclonal antibodies in chicken eggs published in Nature Biotechnology
11. Vietnam war technology could aid elephant conservation
Post Your Comments:
(Date:1/22/2015)... Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication company ... of the Wocket™ smart wallet at CES 2015 in Las ... one of the "11 Hot Products at CES" in a review published ... Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
(Date:1/22/2015)... NEW YORK , Jan. 21, 2015  Analyst Report Issued ... Credit Card Brands report showed that planet-wide, transactions at merchants ... 2011, while the total number of credit, debit, and prepaid ... the U.S. were victims of fraudulent card usage in 2012, ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... of the "Global Wearable Technologies Market and ... Overview, Trends and Forecast 2014-2020" report to ... are smart devices that can be worn on ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... new evidence that dinosaurs were warm-blooded like birds and ... In a paper published in PLoS ONE , ... and Environmental Sciences, argues that cold-blooded dinosaurs would not ... other animals and dominate over mammals as they did ...
... researchers have wondered why ovarian cancer cells are so ... the hope that such an understanding could lead to ... a series of experiments suggest a two-step model of ... to and lodge within immune cell-containing structures known as ...
... , July 17, 2013 ... the " Silicon-based Fingerprint Sensors - Global Strategic ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) This report ... Sensors in US$ Million by the following ...
Cached Biology News:New evidence for warm-blooded dinosaurs 2Ovarian cancer metastases influenced by factors in target tissues 2Ovarian cancer metastases influenced by factors in target tissues 3Silicon-based Fingerprint Sensors - Global Strategic Business Report 2Silicon-based Fingerprint Sensors - Global Strategic Business Report 3
(Date:3/4/2015)... REDWOOD CITY, Calif. , March 4, 2015 ... ACRX ), a specialty pharmaceutical company focused on ... the treatment of acute and breakthrough pain, today ... yearly 2014 financial results after market close on ... an investment-community conference call at 4:30 p.m. Eastern ...
(Date:3/4/2015)... -- Launched by the Assistance Publique ... December 2011, ,SARAH, - the French national collaborative ... in advanced hepatocellular carcinoma (HCC) has enrolled more than ... SARAH, a large French study of patients with advanced, ... completed patient enrolment, exceeding its 400-patient target, according to ...
(Date:3/3/2015)... SAN DIEGO , March 3, 2015  Halozyme Therapeutics, ... the Barclays 2015 Global Healthcare Conference in Miami, ... ET/10:05 a.m. PT. David A. Ramsay , Chief Financial ... will be webcast through the "Investors" section of Halozyme,s corporate ... made available for 90 days following the event. To access ...
(Date:3/3/2015)... and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ) has announced ... - 2025" report to their offering. ... extensive study on the marketed and pipeline gene therapies. ... this field for over a decade but there are ... one approved in the EU). There are many promising ...
Breaking Biology Technology:AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity, ... are as follows:   , , , ... , Time:  8:30am Pacific Time , ... Location: The Ritz-Carlton, San Francisco , , , ...
... , PRINCETON, N.J. , May 10 ... the Company), a late-stage biotechnology company, announced today that ... of Treating Inflammatory Disorders of the Gastrointestinal Tract using ... the use of topically active corticosteroids in orally administered ...
... ... its revolutionary Trusted LASIK Surgeons directory service and website at www.TrustedLASIKSurgeons.com ... their vision and find a highly qualified eye surgeon who can help ... LASIK Surgeons directory apart is a unique screening process ensuring that only ...
Cached Biology Technology:Orexigen(R) Therapeutics to Speak at Ninth Annual JMP Securities Research Conference 2Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders 2Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders 3Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders 4Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders 5Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 2Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 3Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 4Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 5Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 6Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 7Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 8Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 9
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
The Proteome Profiler Human Phospho-MAPK Array Kit contains 4 membranes - each spotted in duplicate with 23 different MAPK antibodies....
Mycoplasma tested...
Recombinant Human PTP1B (aa 2-321), CF...
Biology Products: